Research Article

The Prognostic Significance of Beta2 Microglobulin in Patients with Hemophagocytic Lymphohistiocytosis

Table 1

Baseline demographic and clinical characteristics of patients with HLH.

TotalLAHSBenign disease-associated HLH

Age, yr39.0 (22.3–54.3)44.0 (24.5–54.0)31.0 (19.0–55.0)
Male, number (%)44 (59.5%)28 (68.3%)16 (48.5%)
Fever (>38°C)73 (98.6%)41 (100%)32 (97.0%)
Splenomegaly63 (85.1%)36 (87.8%)27 (81.8%)
Leukocytes, ×109/L2.7 (1.2–4.0)2.6 (1.1–3.7)3.2 (1.5–4.5)
Hemoglobin, g/L86.0 (76.0–103.8)86.0 (72.5–105.0)86.0 (77.0–102.0)
Platelets, ×109/L36.9 (25.0–66.3)36.7 (21.0–83.0)39.0 (25.9–56.0)
Triglycerides, mmol/L2.5 (1.6–3.6)2.7 (2.1–3.8)2.1 (1.5–3.5)
Fibrinogen, g/L1.5 (0.9–2.6)1.3 (0.9–2.6)1.7 (1.1–2.6)
Ferritin, μg/L6268.5 (1975.0–14802.5)6500.0 (1825.5–15000)5973.0 (2023.5–14734.5)
NK cell activity (%)12.4 (9.6–16.3)11.7 (8.4–17.1)12.7 (11.4–16.0)
sCD25 ≥ 2400 U/mL70 (94.6%)40 (97.6%)30 (90.9%)
Hemophagocytosis61 (82.4%)32 (78.0%)29 (87.9%)

Results reported as median (range) or number (%).